Editas Medicine Files 8-K for Financials
Ticker: EDIT · Form: 8-K · Filed: Nov 4, 2024 · CIK: 1650664
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Editas Medicine filed an 8-K for financial reporting - no new material info yet.
AI Summary
Editas Medicine, Inc. filed an 8-K on November 4, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the reporting of these items.
Why It Matters
This filing indicates that Editas Medicine is providing updated financial information and exhibits to the SEC, which is a standard procedural requirement for public companies.
Risk Assessment
Risk Level: low — This is a routine filing to report financial statements and exhibits, not an announcement of significant new risks or events.
Key Players & Entities
- Editas Medicine, Inc. (company) — Registrant
- November 4, 2024 (date) — Date of earliest event reported
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates that it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits,' but the specific details of these financial figures are not provided in the provided text.
What is the primary purpose of this 8-K filing for Editas Medicine?
The primary purpose is to report on the company's results of operations and financial condition, and to file necessary financial statements and exhibits with the SEC.
When was this 8-K filing submitted or effective?
The filing was submitted and is effective as of November 4, 2024.
Where is Editas Medicine, Inc. headquartered?
Editas Medicine, Inc. is headquartered at 11 Hurley Street, Cambridge, Massachusetts 02141.
What is the SIC code for Editas Medicine, Inc.?
The Standard Industrial Classification (SIC) code for Editas Medicine, Inc. is 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-11-04 07:33:30
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share EDIT The Nasdaq Sto
Filing Documents
- edit-20241104.htm (8-K) — 26KB
- editasmedicinepressrelease.htm (EX-99.1) — 77KB
- image_0.jpg (GRAPHIC) — 60KB
- 0001650664-24-000120.txt ( ) — 328KB
- edit-20241104.xsd (EX-101.SCH) — 2KB
- edit-20241104_def.xml (EX-101.DEF) — 3KB
- edit-20241104_lab.xml (EX-101.LAB) — 23KB
- edit-20241104_pre.xml (EX-101.PRE) — 14KB
- edit-20241104_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 4, 2024, Editas Medicine, Inc. (the "Company") issued a press release announcing financial results for the fiscal quarter ended September 30, 2024 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "Filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on November 4, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * This exhibit shall be deemed to be furnished and not filed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDITAS MEDICINE, INC. Date: November 4, 2024 By: /s/ Erick Lucera Erick Lucera Chief Financial Officer